Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and arises from abnormal growth in the squamous cells of the skin’s outermost layer due to cumulative exposure to ultraviolet radiation. Without treatment, cSCC can be...
September 13th, 2019 New X-ray radiotherapy image guidance system and SARRP beamline research platform among advanced new solutions showcased on Xstrahl booth (No. 4028) at American Society for Radiation Oncology annual meeting in Chicago, September 15th-18th....
In their paper “Xstrahl therapy results in tissue conservation and long-term control of melanoma in situ of the lower eyelid” Gerald B Fogarty, Amy Ziebell, Stephanie Nicholls, Susith Kulasekara, Doug Duthie and Krishna Tumuluri present the case of a middle-aged woman...
Non-ablative or mild hyperthermia (HT) has been shown in preclinical and clinical studies as a localized radiosensitizer that enhances the tumoricidal effects of radiation. Most preclinical in vivo HT studies use subcutaneous tumor models which do not adequately...
Xstrahl would like to say a big thank you to all the participants of the SARRP User Meeting hosted by the Xstrahl Life Sciences team on August 25th, 2019, the first day of the ICRR 2019 conference. The SARRP User Meeting brought together SARRP scientists from Europe...
Side effects caused by radiation are a limiting factor to the amount of dose that can be applied to a tumor volume. A novel method to reduce side effects in radiotherapy is the use of spatial fractionation, in which a pattern of sub-millimeter beams (minibeams) is...
A leading San Antonio dermatology center has become the first in Texas to commence advanced skin cancer radiotherapy treatments using the new RADiant treatment system from Xstrahl, global leader in superficial radiotherapy devices to treat non-melanoma skin cancer and...
Glioblastoma (GB) is the most common primary malignant brain tumor in adults. The standard of care consists of maximal possible surgical resection with concomitant radiation therapy (RT) and temozolomide (TMZ). Currently the target volume delineation for RT is based...
PURPOSE: Dose verification in preclinical radiotherapy is often challenged by a lack of standardization in the techniques and technologies commonly employed along with the inherent difficulty of dosimetry associated with small-field kilovoltage sources. As a...
Contact Us